CN Patent

CN121752270A — 曲法罗汀酯

Assigned to Aktra Ingredients · Expires 2026-03-27 · 0y expired

What this patent protects

本文描述了某些曲法罗汀脂肪酸酯和含有一种或多种此类化合物的外用、局部皮肤护理组合物。在一些实施方案中，在皮肤中水解后，较短链曲法罗汀脂肪酸酯释放短链脂肪酸如辛酸和月桂酸，已知其有助于局部皮肤递送中的渗透增强。还描述了将外用组合物局部施用于受试者的皮肤以抑制或减少光老化或痤疮体征的方法。

USPTO Abstract

本文描述了某些曲法罗汀脂肪酸酯和含有一种或多种此类化合物的外用、局部皮肤护理组合物。在一些实施方案中，在皮肤中水解后，较短链曲法罗汀脂肪酸酯释放短链脂肪酸如辛酸和月桂酸，已知其有助于局部皮肤递送中的渗透增强。还描述了将外用组合物局部施用于受试者的皮肤以抑制或减少光老化或痤疮体征的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN121752270A
Jurisdiction
CN
Classification
—
Expires
2026-03-27
Drug substance claim
No
Drug product claim
No
Assignee
Aktra Ingredients
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.